You just read:

At Twelve Months Post-Launch, the Majority of Surveyed Oncologists Have Prescribed Xtandi to Their Docetaxel-Pretreated Metastatic Castrate-Resistant Prostate Cancer Patients

News provided by

BioTrends Research Group

Dec 09, 2013, 12:00 ET